Key Highlights

  • Net product Revenue from Zunveyl was USD 7.8 million in the third quarter, up 30% from USD 6.0 million in the second quarter and more than 230% above USD 2.3 million a year earlier.
  • Net loss was USD 7.6 million, or USD 0.35 per share, compared with USD 8.2 million, or USD 0.38, in the second quarter, while the operating loss narrowed to USD 6.4 million.
  • Operating expenses were USD 13.7 million, about USD 12.4 million of selling and administrative cost and USD 1.3 million of research, against USD 12.9 million in the second quarter.
  • Cash and cash equivalents were USD 37.8 million on September 30, 2026, down from USD 41.4 million at June 30, and management said the company has no debt.

Zunveyl Sales Climb 30% in One Quarter

Alpha Cognition (NASDAQ:ACOG) held its third quarter 2026 results call on November 11, 2026, the same day it issued its results release. The company sells Zunveyl, an oral Alzheimer's treatment it describes as the first new one of its type approved in more than a decade, mainly into long-term care. Net product revenue of USD 7.8 million came with a GAAP gross product Margin of 94%, unchanged from the prior quarter. Management said net revenue per prescription held near USD 650, so growth came from volume, not price. Management called it the strongest quarter since launch, with more than 30,000 prescriptions filled across six quarters of commercialization. A prior-quarter 10-Q filed in August serves only as background to this call.

Prescriber Growth, Facilities and Payer Access

Executives said the number of prescribers writing Zunveyl in the quarter rose 23% from the second quarter to 1,150, and cumulative writers reached 2,440, above the original full-year goal of about 2,000 and heading toward a revised goal of 2,500. Homes with a prescription rose 29% to 1,400, and 80% placed repeat orders. They also said 95% of prescriptions were approved where the company's reimbursement team supported prior authorization, and that 70% of long-term care lives have access with a USD 0 copay. Management said it saw no meaningful formulary change in the quarter.

Spending Discipline, Guidance and Pipeline Setbacks

Management said spending was roughly flat while revenue grew 30%, and that the company still targets operating profitability in 2027. It reiterated 2026 Operating Expense guidance of USD 50 million to USD 54 million, with about USD 37.5 million spent through nine months. The net loss included about USD 1.2 million of nonoperating items, mainly a non-cash charge tied to the Fair Value of Warrant liabilities. On development, a sublingual pharmacokinetic study ended in early October with inconclusive data, and an additional study is planned for early January. A behavioral-symptoms trial has enrolled over 57 patients, with completion expected in the second half of 2027.

Where Things Stand

Closer, but not there yet. Alpha Cognition (NASDAQ:ACOG) grew Zunveyl revenue 30% in a quarter, kept spending nearly flat and cut its operating loss to USD 6.4 million, yet it still lost USD 7.6 million and burned about USD 3.6 million of cash. Management targets operating profitability in 2027, which remains a stated goal, not a result. Watch fourth-quarter prescriptions, the pace of cash use against USD 37.8 million on hand, the January sublingual study and further real-world data releases.